Übersicht
- Industrie - Verarbeitendes Gewerbe/Herstellung von Waren
The project supports research, development and clinical evaluation of an implantable neurostimulation device used as a treatment for patients suffering from chronic migraine and cluster headache.
The project supports the Research, Development and Innovation (RDI) activities of a medical technology company specialised in developing innovative neuromodulation solutions for chronic migraine and other severe headache disorders. Its technology aims to provide therapeutic options for conditions with significant unmet medical needs, thereby strengthening innovation in the field of bioelectronic medicine.
The specific RDI activities included in the project are expected to be performed in existing facilities without changing their already authorised scope. Therefore, the project activities would not require an Environmental Impact Assessment (EIA) under the Directive 2014/52/EU (amending the Directive 2011/52/EU). Full environmental details will be verified during appraisal.
The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is generally not covered by EU directives on procurement. However, the EIB will require that all project contracts are procured in accordance with the applicable EU procurement legislation. The Bank's services will verify details during the project due diligence.